The progression of pathology in Parkinson's disease
- PMID: 20146698
- DOI: 10.1111/j.1749-6632.2009.05118.x
The progression of pathology in Parkinson's disease
Abstract
To identify the progression of pathology over the entire course of Parkinson's disease, we longitudinally followed a clinical cohort to autopsy and identified three clinicopathological phenotypes that progress at different rates. Typical Parkinson's disease has an initial rapid loss of midbrain dopamine neurons with a slow progression of Lewy body infiltration into the brain (over decades). Dementia intervenes late when Lewy bodies invade the neocortex. Older onset patients (> 70 years old) dement earlier and have much shorter disease durations. Paradoxically, they have far more alpha-synuclein-containing Lewy bodies throughout the brain, and many also have additional age-related plaque pathology. In contrast, dementia with Lewy bodies has the shortest disease course, with substantive amounts of Lewy bodies and Alzheimer-type pathologies infiltrating the brain. These data suggest that two age-related factors influence pathological progression in Parkinson's disease--the age at symptom onset and the degree and type of age-related Alzheimer-type pathology.
Similar articles
-
The progression of pathology in longitudinally followed patients with Parkinson's disease.Acta Neuropathol. 2008 Apr;115(4):409-15. doi: 10.1007/s00401-008-0344-8. Epub 2008 Jan 30. Acta Neuropathol. 2008. PMID: 18231798
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
Parkinson's disease dementia: what's in a Lewy body?J Neural Transm Suppl. 2006;(70):361-5. J Neural Transm Suppl. 2006. PMID: 17017554 Review.
-
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.Brain. 2010 Jun;133(Pt 6):1755-62. doi: 10.1093/brain/awq059. Epub 2010 Apr 5. Brain. 2010. PMID: 20371510
-
Research in motion: the enigma of Parkinson's disease pathology spread.Nat Rev Neurosci. 2008 Oct;9(10):741-5. doi: 10.1038/nrn2477. Epub 2008 Sep 4. Nat Rev Neurosci. 2008. PMID: 18769444 Review.
Cited by
-
Multimodal neuroimaging to characterize symptom-specific networks in movement disorders.NPJ Parkinsons Dis. 2024 Aug 14;10(1):154. doi: 10.1038/s41531-024-00774-3. NPJ Parkinsons Dis. 2024. PMID: 39143114 Free PMC article. Review.
-
Lipid pathway alterations in Parkinson's disease primary visual cortex.PLoS One. 2011 Feb 28;6(2):e17299. doi: 10.1371/journal.pone.0017299. PLoS One. 2011. PMID: 21387008 Free PMC article.
-
Is Braak staging valid for all types of Parkinson's disease?J Neural Transm (Vienna). 2019 Apr;126(4):423-431. doi: 10.1007/s00702-018-1898-9. Epub 2018 Jun 25. J Neural Transm (Vienna). 2019. PMID: 29943229 Review.
-
BAG2 structure, function and involvement in disease.Cell Mol Biol Lett. 2016 Sep 20;21:18. doi: 10.1186/s11658-016-0020-2. eCollection 2016. Cell Mol Biol Lett. 2016. PMID: 28536620 Free PMC article. Review.
-
Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson's disease.Commun Med (Lond). 2025 Apr 27;5(1):141. doi: 10.1038/s43856-025-00817-7. Commun Med (Lond). 2025. PMID: 40289204 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical